

Vasily M Gelfanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103679/publications.pdf>

Version: 2024-02-01

46
papers

3,471
citations

361413

20
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

3225
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes. <i>Cell Reports Medicine</i> , 2022, 3, 100598.	6.5	6
2	Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4697-4708.	6.4	12
3	A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor. <i>Molecular Metabolism</i> , 2021, 53, 101316.	6.5	9
4	Addition of Sialic Acid to Insulin Confers Superior Physical Properties and Bioequivalence. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6134-6143.	6.4	11
5	Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice. <i>Peptides</i> , 2019, 120, 170116.	2.4	9
6	A Disulfide Scan of Insulin by [3 + 1] Methodology Exhibits Site-Specific Influence on Bioactivity. <i>ACS Chemical Biology</i> , 2019, 14, 1829-1835.	3.4	10
7	Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. <i>Molecular Metabolism</i> , 2019, 20, 51-62.	6.5	130
8	The islet-expressed Lhx1 transcription factor interacts with Islet-1 and contributes to glucose homeostasis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E397-E409.	3.5	11
9	Structurally Constrained Insulin Analogs by Directed Stepwise Crosslinking. <i>Protein and Peptide Letters</i> , 2019, 25, 1149-1154.	0.9	0
10	Viral insulin-like peptides activate human insulin and IGF-1 receptor signaling: A paradigm shift for host-microbe interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2461-2466.	7.1	63
11	Synthesis and Characterization of the R27S Genetic Variant of Insulin-like Peptide 5. <i>ChemMedChem</i> , 2018, 13, 852-859.	3.2	4
12	Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity. <i>Peptides</i> , 2018, 100, 18-23.	2.4	6
13	Max Bergmann award lecture: Macromolecular medicinal chemistry as applied to metabolic diseases. <i>Journal of Peptide Science</i> , 2018, 24, e3056.	1.4	1
14	Optimization of peptide-based polyagonists for treatment of diabetes and obesity. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2873-2881.	3.0	18
15	Synthesis of disulfide-rich heterodimeric peptides through an auxiliary N, N-crosslink. <i>Communications Chemistry</i> , 2018, 1, .	4.5	10
16	High-Yield Synthesis of Human Insulin-Like Peptide 5 Employing a Nonconventional Strategy. <i>Organic Letters</i> , 2018, 20, 3695-3699.	4.6	8
17	Biomimetic Synthesis of Insulin Enabled by Oxime Ligation and Traceless C-Peptide-Chemical Excision. <i>Organic Letters</i> , 2017, 19, 706-709.	4.6	20
18	Synthesis of relaxin and insulin-like peptide 5 enabled by novel tethering and traceless chemical excision. <i>Journal of Peptide Science</i> , 2017, 23, 455-465.	1.4	13

#	ARTICLE	IF	CITATIONS
19	Synthesis of Four-Disulfide Insulin Analogs via Sequential Disulfide Bond Formation. Journal of Organic Chemistry, 2017, 82, 3506-3512.	3.2	29
20	Synthetic Advances in Insulin-like Peptides Enable Novel Bioactivity. Accounts of Chemical Research, 2017, 50, 1855-1865.	15.6	15
21	Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism, 2016, 24, 51-62.	16.2	198
22	Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell, 2016, 167, 843-857.e14.	28.9	153
23	Pyridyl-alanine as a Hydrophilic, Aromatic Element in Peptide Structural Optimization. Journal of Medicinal Chemistry, 2016, 59, 8061-8067.	6.4	11
24	Synthetic Route to Human Relaxin-2 via Iodine-Free Sequential Disulfide Bond Formation. Organic Letters, 2016, 18, 5516-5519.	4.6	16
25	Three-chain insulin analogs demonstrate the importance of insulin secondary structure to bioactivity. Journal of Peptide Science, 2015, 21, 223-230.	1.4	1
26	A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 2015, 21, 27-36.	30.7	481
27	A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia. Molecular Metabolism, 2014, 3, 293-300.	6.5	33
28	Chemical Synthesis of Insulin Analogs through a Novel Precursor. ACS Chemical Biology, 2014, 9, 683-691.	3.4	38
29	Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. Science Translational Medicine, 2013, 5, 209ra151.	12.4	461
30	A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction. Molecular Metabolism, 2013, 2, 86-91.	6.5	13
31	Peptide lipidation stabilizes structure to enhance biological function. Molecular Metabolism, 2013, 2, 468-479.	6.5	83
32	Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions. Diabetes, 2013, 62, 1453-1463.	0.6	191
33	Discovery of High Potency, Single-Chain Insulin Analogs with a Shortened B-Chain and Nonpeptide Linker. ACS Chemical Biology, 2013, 8, 1822-1829.	3.4	5
34	Optimization of coagonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO rodents. Biopolymers, 2012, 98, 443-450.	2.4	110
35	Targeted estrogen delivery reverses the metabolic syndrome. Nature Medicine, 2012, 18, 1847-1856.	30.7	241
36	A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1. ACS Chemical Biology, 2011, 6, 135-145.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. Journal of Peptide Science, 2011, 17, 218-225.	1.4	23
38	Functional association of the N-terminal residues with the central region in glucagon-related peptides. Journal of Peptide Science, 2011, 17, 659-666.	1.4	16
39	Optimization of the Native Glucagon Sequence for Medicinal Purposes. Journal of Diabetes Science and Technology, 2010, 4, 1322-1331.	2.2	53
40	Glucagon regulation of energy metabolism. Physiology and Behavior, 2010, 100, 545-548.	2.1	62
41	A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology, 2009, 5, 749-757.	8.0	512
42	Synthesis and Biological Assessment of Insulin-Like Analogs with Differential Activity at the Insulin and IGF-1 Receptors. , 2006, , 229-234.		2
43	Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor κ B-mediated antiapoptosis involving c-IAP2. Blood, 2001, 98, 2508-2517.	1.4	37
44	Paclitaxel sensitivity of breast cancer cells with constitutively active NF- κ B is enhanced by κ B super-repressor and parthenolide. Oncogene, 2000, 19, 4159-4169.	5.9	277
45	Distinct actions of interleukin-9 and interleukin-4 on a hematopoietic stem cell line, EMLC1. Experimental Hematology, 1999, 27, 139-146.	0.4	7
46	New virus-specific T-helper epitopes of foot-and-mouth disease viral VP1 protein. FEBS Letters, 1993, 333, 175-178.	2.8	17